Do you need a recap of the latest urologic oncology research presented at GU ASCO 2025? This episode of BackTable Urology features a multidisciplinary discussion among three leading voices in urology and medical oncology – Drs. Bogdana Schmidt, Shilpa Gupta, and Ben Maughan – covering the most notable results presented at this year’s meeting.

---

This podcast is supported by:

Photocure

https://www.photocure.com/

---

SYNPOSIS

First, the doctors cover a wide range of topics including PARP inhibitors for prostate cancer, HER2-targeting antibody drug conjugates in bladder cancer, adjuvant chemotherapy for upper tract urothelial carcinoma, and biomarkers such as KIM-1 in kidney cancer. Highlighting the importance of multidisciplinary collaboration, the experts also critique the COSMIC-313 trial and discuss the nuances of applying new therapeutic combinations in real-world clinical practice.

---

TIMESTAMPS

00:00 - Introduction

09:20 - TALAPRO-2 Trial Insights

19:29 - Bladder Cancer: Immuno-Oncology Combinations and HER2

27:42 - NIAGARA and iNDUCT Trials

33:32 - Future Directions in Upper Tract Treatment

37:38 - Biomarkers in Kidney Cancer: KIM-1

46:43 - COSMIC-313: Triplet Therapy in Renal Cell Carcinoma

52:39 - Concluding Thoughts and Future Directions

---

RESOURCES

Photocure:

https://www.photocure.com/